Novavax (NVAX) can't gain any traction despite promising data points for both RSV and Flu vaccines. The problem as usual is that Novavax shifted the upcoming milestones from RSV data to the NanoFlu program. The company now seems more focused on Phase 1 flu trials over the previous crucial Phase 2/3 trials from RSV. Cash was a big concern with just RSV and Novavax continues to include more expenses from expanding the pipeline while the market wants to see some proof that the management team can get vaccines approved. For this reason, Novavax remains a call option to buy near $1. Just don't chase rallies. Disclosure: No position